A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer

A Phase II Clinical Study of Stereotactic Radiation Therapy Based on Multiparameter Magnetic Resonance Image in Patients With High-risk Prostate Cancer

Stereotactic body radiotherapy (SBRT) has emerged as an effective and safe treatment for low and intermediate-risk prostate cancer(PCa). However, there is no study that has investigated the effectiveness and safety of SBRT with pelvic radiation and gross target volume(GTV) boost for high-risk prostate cancer patients yet. The investigators designed a phase II clinical study of SBRT with pelvic radiation and GTV boost based on mpMRI in patients with high-risk prostate cancer.

Inclusion Criteria:

• 18 years or older
• pathologically confirmed high-risk (T3a or Gleason score ≥ 8 or a PSA > 20 ng/ml) prostate cancer
• a WHO performance status 0-1
• history of neoadjuvant androgen deprivation therapy(ADT) within 6 months before enrollment
• Patients with pelvic positive lymph node were also included in our study

Exclusion Criteria:

• distant metastasis
• history of neoadjuvant ADT over 6 months before enrollment
• history of definitive treatment for prostate cancer such as radical prostatectomy
• history of pelvic irradiation; prostate volume≥100 cm3